Herz Und Diabeteszentrum NRW Bad Oeynhausen Universitaetsklinik Der Ruhr-Universitaet Bochum
Verified site
Bad Oeynhausen, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
People with Type 2 Diabetes whose blood sugar is not well controlled despite using basal insulin may receive a new injectable medicine called maridebart cafraglutide (code name AMG 133) or a harmless substance known as placebo during the study.
The aim of the research is to find out whether the new medicine can lower blood sugar better than the placebo, as measured by a blood test called HbA1c. Additional goals include looking at changes in body weight and whether participants can reach target blood‑sugar levels.
People are assigned to one of the two groups by chance and neither the participants nor the study staff know which treatment is given. The assigned injection is given under the skin at regular visits, and participants attend scheduled appointments for safety checks, blood tests, and other routine assessments over the study period.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
8 criteria
33 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Bad Oeynhausen, Germany
A Coruna Galicia, Spain
Gdansk, Poland
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
AMG 133 is an experimental injection that contains the active ingredient maridebart cafraglutide. In this study, participants receive the medicine under the skin (subcutaneous use) as a liquid solution. The drug is being tested to see if it can help lower blood sugar levels in people with type 2 diabetes who are already using basal insulin.
This medication is given as a clear solution that is injected under the skin. It is still being studied in late‑stage clinical trials and is not yet approved for regular medical use. It is aimed at people with type 2 diabetes whose blood sugar is not well controlled with basal insulin. The drug works by copying a natural hormone that tells the pancreas to release more insulin after meals and helps lower appetite, and it belongs to the class of GLP‑1 receptor agonists.
The placebo is a harmless liquid that is also injected under the skin, but it contains no active drug. It is used only in research studies to compare the effects of the real medication. It has no therapeutic purpose or known action in the body. The placebo serves as a control to help scientists see whether the test drug truly works.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.